Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (November 2018)
22 slides from Monash Ivf's shareholder meeting presentation, Nov 22, 2018
Slide 1: Life starts here – Annual General Meeting
For personal use only Life starts here Annual General Meeting 22 November 2018
Slide 2: Disclaimer
Disclaimer For personal use only The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The info
Slide 3: Chairman's address
Chairman’s address For personal use only Richard Davis 3 Monash IVF Group | Annual General Meeting 2018
Slide 4: Key Achievements
Key Achievements For personal use only Strategic roadmap progressed which has confirmed our position as a leading premium service provider FY18 was challenging given departure of CEO and departure of a high volume Victorian Fertility Specialist Our Australian ARS Premium Service business remai
Slide 5: FY2019 Trading Update
FY2019 Trading Update For personal use only In the first quarter, the Australian Stimulated Cycle market increased by 2.8% compared to PCP, broadly in line with the long-term industry growth rate. In the first quarter, Our Australian Stimulated Cycles declined by 8.0%. (Importantly, excluding th
Slide 6: Thank you
Thank you For personal use only The last 18 months have been a tumultuous period for the Business with the loss of a Specialist and departure of two CEOs. I would like to thank the Management Team, dedicated specialists, nurses, scientists and other staff for continuing to provide our patients w
Slide 7: Interim CEO presentation
Interim CEO presentation For personal use only Michael Knaap 7 Monash IVF Group | Annual General Meeting 2018
Slide 8: Overview of Monash IVF Group
Overview of Monash IVF Group For personal use only Monash IVF Group is a market leader in fertility ARS Diagnostic Ultrasound 22 clinics2 2 specialised 18 clinics laboratories (VIC and 5 service centres SA) 15 Sonologists 91 Fertility Specialists 4 Australian states 3 day hospitals (
Slide 9: MVF long term performance
MVF long term performance For personal use only We have had a track record of solid performance against the 5‐year Stimulated Cycle industry CAGR of 1.7%, however FY18 activity has been significantly impacted by the departure of a Specialist. Stimulated Cycles Revenue ($m) 156.6 155.2 150.6 9,807 9,
Slide 10: Financial and Operational Highlights
Financial and Operational For personal use only Highlights 10 Monash IVF Group | Annual General Meeting 2018
Slide 11: FY18 Financial Summary
FY18 Financial Summary For personal use only 1 Revenue EBITDA FY18 Dividends $150.6m $38.1m 6.0c FY17 $155.2m FY17 $49.0m FY17 8.8 cents Down 2.9% Down 22.2% Down 31.8% 2 3 NPAT Cash Conversion Basic EPS $21.4m 93.3% 9.1c FY17 $29.6m FY17 93.9% FY17 12.6 cents Down 27.9% Down 0.6% Down 27.8% 1. Earn
Slide 12: ARS Australia - Operational Performance
ARS Australia - Operational Performance For personal use only Operational performance has been significantly impacted by the departure of a Specialist. Premium Full Service business (excluding the impact from a departing Specialist) remains solid, demonstrating 3.0% Stimulated Cycle growth in our
Slide 13: Australian IVF market movement and growth
Australian IVF market movement and growth For personal use only Stimulated Cycles in Key Markets1 declined by 0.6% in FY18 vs FY17. Our view is that the long‐ term Stimulated Cycle growth rate will be approximately 2.0%. Stimulated Cycle Growth Rates in our Key Markets1 Number of Australian Stimulat
Slide 14: Diagnostics Performance
Diagnostics Performance For personal use only Diagnostics continues to grow as we build our in‐house capabilities and leverage our Ultrasound footprint. NIPT volumes increased by 32.4% from 9,834 to 13,017 of which 99.1% was performed in-house (37.3% pcp). This has enhanced our Ultrasound service
Slide 15: ARS International Performance
ARS International Performance For personal use only ARS International EBITDA grew 50.2% and now represents 9.9% of Group EBITDA. ARS revenue increased by 40.5% from $6.2m to $8.8m as Stimulated Cycles increased by 23.2% from 689 to 849. Total Patient Treatments increased by 24.2% from 1,346 to 1,6
Slide 16: FY19 – Strategy and Trading Update
FY19 – Strategy and For personal use only Trading Update 16 Monash IVF Group | Annual General Meeting 2018
Slide 17: Strategic priorities
Strategic priorities For personal use only Our strategic priorities will drive growth and create sustainable shareholder value… Focus on our Premium Fertility offering for Premium Fertility women and men; including holistic Fertility Solutions Solutions Fertility (Women and Men) Increase the integra
Slide 18: Operating priorities
Operating priorities We continue to focus on operating priorities of Scientific Leadership, Clinical Excellence and For personal use only Customer (Patient) Experience. Harmonise scientific methods and invest in laboratories with state of the art Scientific technology and equipment to continue to su
Slide 19: Operating priorities
Operating priorities For personal use only Strategic Roadmap progressed to deliver sustainable growth in our Organisation Scientific Leadership Clinical Excellence Patient Experience World-first internal roll out of Investment in our facilities Patient Journey review non-invasive PGS The ‘Mo
Slide 20: FY19 Trading Update
FY19 Trading Update For personal use only Key Markets1 Stimulated Cycle market grows inline with long‐term growth rate during Q1FY19 Total Key Markets1 Stimulated Cycle market has grown by 2.8% during Q1FY19 as compared to the prior corresponding Stimulated Cycle Growth Rates in Key Markets1 perio
Slide 21: FY19 Trading Update - Continued
FY19 Trading Update - Continued For personal use only Monash IVF Group is well positioned to return to growth Fertility Specialist recruited – eight new specialists attracted during FY18 contributing to Q1FY19 growth in SA, NSW and Malaysia 17.6% Stimulated Cycle growth achieved in Q1FY19 outsid
Slide 22: Summary
Summary For personal use only FY18 earnings impacted from departure of Fertility Specialist Industry Stimulated Cycles declined in FY18 with a large decline in H2FY18 Strategic Roadmap progressed to deliver sustainable shareholder growth Australian Premium Full Service Business fundamentals
Monash IVF Group — Shareholder Meeting (November 2018) on 6ix